NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.37 billion. The enterprise value is $1.13 billion.
Important Dates
The last earnings date was Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 111.98 million shares outstanding. The number of shares has increased by 2.82% in one year.
| Current Share Class | 111.98M |
| Shares Outstanding | 111.98M |
| Shares Change (YoY) | +2.82% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 9.67% |
| Owned by Institutions (%) | 77.84% |
| Float | 94.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.10 |
| Forward PS | 2.05 |
| PB Ratio | 4.01 |
| P/TBV Ratio | 4.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 2.34.
| Current Ratio | 1.55 |
| Quick Ratio | 1.49 |
| Debt / Equity | 2.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.71 |
Financial Efficiency
Return on equity (ROE) is -50.60% and return on invested capital (ROIC) is -9.98%.
| Return on Equity (ROE) | -50.60% |
| Return on Assets (ROA) | -8.41% |
| Return on Invested Capital (ROIC) | -9.98% |
| Return on Capital Employed (ROCE) | -29.69% |
| Revenue Per Employee | $431,632 |
| Profits Per Employee | -$119,388 |
| Employee Count | 1,488 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 4.02 |
Taxes
In the past 12 months, NovoCure has paid $27.15 million in taxes.
| Income Tax | 27.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.41% in the last 52 weeks. The beta is 0.83, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -24.41% |
| 50-Day Moving Average | 13.11 |
| 200-Day Moving Average | 16.74 |
| Relative Strength Index (RSI) | 35.26 |
| Average Volume (20 Days) | 1,287,149 |
Short Selling Information
The latest short interest is 5.24 million, so 4.68% of the outstanding shares have been sold short.
| Short Interest | 5.24M |
| Short Previous Month | 5.75M |
| Short % of Shares Out | 4.68% |
| Short % of Float | 5.56% |
| Short Ratio (days to cover) | 2.84 |
Income Statement
In the last 12 months, NovoCure had revenue of $642.27 million and -$177.65 million in losses. Loss per share was -$1.61.
| Revenue | 642.27M |
| Gross Profit | 485.09M |
| Operating Income | -173.75M |
| Pretax Income | -150.50M |
| Net Income | -177.65M |
| EBITDA | -161.59M |
| EBIT | -173.75M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $1.03 billion in cash and $797.94 million in debt, giving a net cash position of $235.56 million or $2.10 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 797.94M |
| Net Cash | 235.56M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 341.33M |
| Book Value Per Share | 3.05 |
| Working Capital | 423.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.48 million and capital expenditures -$30.69 million, giving a free cash flow of -$65.17 million.
| Operating Cash Flow | -34.48M |
| Capital Expenditures | -30.69M |
| Free Cash Flow | -65.17M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
Gross margin is 75.53%, with operating and profit margins of -27.05% and -27.66%.
| Gross Margin | 75.53% |
| Operating Margin | -27.05% |
| Pretax Margin | -23.43% |
| Profit Margin | -27.66% |
| EBITDA Margin | -25.16% |
| EBIT Margin | -27.05% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.82% |
| Shareholder Yield | -2.82% |
| Earnings Yield | -12.97% |
| FCF Yield | -4.76% |
Dividend DetailsAnalyst Forecast
The average price target for NovoCure is $28.64, which is 134.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.64 |
| Price Target Difference | 134.18% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 19.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.32 |
| Piotroski F-Score | 3 |
